Chemical firm Bayer is to pay up to $10.9bn (£8.8bn) to settle cancer claims linked to its Roundup weedkiller.
The glyphosate-based product has been subject to about 125,000 lawsuits over its allegedly carcinogenic effects.
New York-based law firm Weitz & Luxenberg says it has reached a settlement on behalf of almost 100,000 people.
Bayer denies any wrongdoing but said the payout would end "uncertainty".
Roundup was originally launched by US firm Monsanto, which bought by Bayer in 2018.
Since its introduction more than four decades ago, it has become known as the world's most popular weedkiller,
As part of the settlement, Bayer will pay as much as $9.6bn to resolve outstanding claims, and set aside a further $1.25bn to deal with any future action, the company said in a statement on its website.
"It has been a long journey, but we are very pleased that we've achieved justice for the tens of thousands of people who, through no fault of their own, are suffering from Non-Hodgkin Lymphoma after using a product Monsanto assured them was safe," Robin Greenwald, Practice Group Chair, Environmental Pollution and Consumer Protection at Weitz & Luxenberg, said in a statement.
Up to $5bn of the agreed payout will be released this year, with a further $5bn paid in 2021. Bayer said an agreement had not yet been reached for about 25% of the outstanding claims.
"First and foremost, the Roundup settlement is the right action at the right time for Bayer to bring a long period of uncertainty to an end," wrote Werner Baumann, chief executive of Bayer.
He repeated the company's view that the science indicates "Roundup does not cause cancer, and therefore, is not responsible for the illnesses alleged in this litigation".
Bans on glyphosate
The German chemical giant bought Monsanto for $63bn two years ago and immediately faced legal battles over the herbicide.
In August 2018, a California court issued the first ruling linking Roundup to cancer, awarding claimants substantial compensation.
In their lawsuits, users bRead More – Source